This payment is related to the transfer of Alnylam’s platform technology, including documents, materials, and know-how, to Takeda for the development of RNAi therapeutics. Alnylam has already received
The patent contains claims directed to inhibitory nucleic acid sequences targeting the ribonucleotide reductase subunit 2 (R2) gene, as well as pharmaceutical compositions and methods for inhibiting tumor
The trial, called Protex I, will enroll 50 patients at five sites in Europe. Follow-up examinations will be performed at 30 days, six months and nine months. The
Additionally, the company has also signed an agreement for distribution of the SmartSlide micro-incubation system with Takeda Rika Kogyo in Japan. These distributor agreements cover WaferGen’s entire family
Mr O’Connor has held positions as vice president of sales, business development manager, and North America sales manager for companies such as Luminex. Mr O’Connor will be based
This milestone officially marks the completion of this randomized, double-blind, placebo-controlled Phase IIb clinical trial which enrolled 351 patients at approximately 40 sites in the US, Germany, Israel
Dr Radaelli is the president and CEO of Dompe International. He currently serves on the board of directors of Dompe Farmaceutici SpA, Dompe SpA, and Philogen SpA, a
This Phase II clinical trial is designed as a double-blind, placebo-controlled Phase II trial which would evaluate safety and efficacy of oral flupirtine versus placebo in fibromyalgia patients.
AnGes plans to conduct due diligence on the pandemic influenza DNA vaccines, and both parties intend to negotiate terms and conditions potentially leading to a license, subject to
The main objective of the multi-center, open-label, safety and efficacy study is to assess patients’ overall response rate to a regimen combining bavituximab with the chemotherapy drugs carboplatin
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.